Research programme: mucosal vaccines - Mucosis

Drug Profile

Research programme: mucosal vaccines - Mucosis

Alternative Names: Hepatitis B vaccine - Mucosis; Malaria vaccine - Mucosis; Plague vaccine - Mucosis; PneuGEM; Shigella and other enteric bacterial pathogens vaccines - Mucosis; Yersinia pestis vaccine - Mucosis

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Mucosis
  • Developer Mucosis; University of Copenhagen
  • Class Antibodies; Bacterial vaccines; Glycoproteins; Hepatitis B vaccines; Membrane fusion proteins; Parasitic vaccines; Pneumococcal vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B; Otitis media; Pneumonia; Respiratory syncytial virus infections; Shigella infections; Yersinia infections
  • No development reported Malaria; Pneumococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria(Prevention) in Netherlands (Intranasal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections(Prevention) in Netherlands (Intranasal)
  • 27 Oct 2014 Preclinical trials in Otitis media (Prevention, In children) in Netherlands (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top